Laila Poisson

Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas

This study identifies genetic changes in IDH-mutant gliomas that correlate with treatment response and tumor evolution using longitudinal genomic data from 206 patient samples.

Impact of genomic background and developmental state on signaling pathways and response to therapy in Glioblastoma patient-derived cells

This study examines how genomic background and developmental state affect signaling pathways and therapy response in GBM patient-derived cells, finding that differentiation increases TMZ resistance and activates DNA-damage interferon responses.

Utility of an untargeted metabolomics approach using a 2D GC-GC-MS platform to distinguish relapsing and progressive multiple sclerosis

This study uses untargeted metabolomics to identify altered serum metabolites distinguishing relapsing-remitting MS, progressive MS, and healthy subjects.

The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen

This study analyzes the epigenetic evolution of IDH1-mutant and IDH1-wildtype gliomas under treatment, showing IDHmut tumors undergo epigenomic changes resembling IDHwt tumors, with implications for treatment strategies.

iPSC-derived astrocytes to model phenotype-specific differential neuroinflammatory and metabolic responses in X-linked adrenoleukodystrophy

This study uses iPSC-derived astrocytes to compare metabolic and inflammatory responses between AMN and cALD phenotypes in X-ALD, identifying miR-9 as associated with disease severity.

Blood-based untargeted metabolomics in Relapsing-Remitting Multiple Sclerosis revealed the testable therapeutic target

The paper identifies altered metabolic pathways in RRMS patients using metabolomics and shows that targeting glycolysis can reduce disease progression in a mouse model.

Distinct epigenetic shift in a subset of Glioma CpG island methylator phenotype (G-CIMP) during tumor recurrence

The paper identifies an epigenetic shift from G-CIMP-high to G-CIMP-low in gliomas during recurrence, associated with genomic instability and stem cell-like features, and proposes biomarkers for predicting recurrence.